Novel approaches to create selective antibody biocatalysts to speed up chemical reactions have made much progress. It is now time to apply the recent developments in catalytic antibody design to important human clinical toxicological problems. For example, it is clear that an anti- cocaine antibody with selective esterolytic action could lead to the detoxication of cocaine. The central hypothesis of our work is that a """"""""transition state mimic"""""""" hapten of cocaine hydrolysis elicits an immune response that affords anti-cocaine catalytic esterolytic activity. Using chemical, immunological and molecular approaches we have developed several unique methods for the production of esterolytic catalytic antibodies. The studies are divided into 3 major sections: (1) Chemical synthesis of """"""""transition state analogs"""""""" of cocaine ester hydrolysis, (2) Novel selection strategies to identify monoclonal anti-cocaine catalytic esterolytic and non-esterolytic high affinity antibodies, and (3) Cloning, sequencing and expression of active anti-cocaine esterolytic antibody domains.
The specific aims of section l are to synthesize transition state mimics of cocaine hydrolysis and to procure esterolytic and non- esterolytic antibodies.
The specific aims of section 2 are: a) to select esterolytic catalytic and """"""""tight-binding"""""""" anti-cocaine monoclonal antibodies and characterize the kinetic properties, substrate specificity and protein structural features.
The specific aims of section 3 are: a) to isolate and sequence the cDNA encoding the catalytic antibodies identified in Sections 1 and 2 and to express the cDNA of the variable active fragments in E. coli and b) to characterize the kinetics, substrate specificity and structural properties of the expressed fragments. The parallel in vitro-in vivo experimental design will permit the direct testing of the central hypothesis. The procurement of anti-cocaine catalytic antibodies and active anti-cocaine recombinant antibody fragments provides an opportunity to experimentally answer important basic molecular questions which have direct benefits for human cocaine detoxication.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008531-05
Application #
2458402
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1993-09-30
Project End
1998-02-28
Budget Start
1997-08-20
Budget End
1998-02-28
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Seattle Biomedical Research Institute
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98109
Feng, Xianqi; Fandrick, Keith; Johnson, Robert et al. (2003) Syntheses of 3-carbomethoxy-4-(aryl)piperidines and in vitro and in vivo pharmacological evaluation: identification of inhibitors of the human dopamine transporter. Bioorg Med Chem 11:775-80
Cashman, J R; Berkman, C E; Underiner, G E (2000) Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J Pharmacol Exp Ther 293:952-61
Xie, W; Altamirano, C V; Bartels, C F et al. (1999) An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55:83-91
Cashman, J R; Berkman, C E; Underiner, G et al. (1998) Cocaine benzoyl thioester: synthesis, kinetics of base hydrolysis, and application to the assay of cocaine esterases. Chem Res Toxicol 11:895-901
Berkman, C E; Underiner, G E; Cashman, J R (1997) Stereoselective inhibition of human butyrylcholinesterase by phosphonothiolate analogs of (+)- and (-)-cocaine. Biochem Pharmacol 54:1261-6
Lin, J; Cashman, J R (1997) Detoxication of tyramine by the flavin-containing monooxygenase: stereoselective formation of the trans oxime. Chem Res Toxicol 10:842-52
Cashman, J R (1997) Biocatalysts in detoxication of drugs of abuse. NIDA Res Monogr 173:225-58
Cashman, J R; Perotti, B Y; Berkman, C E et al. (1996) Pharmacokinetics and molecular detoxication. Environ Health Perspect 104 Suppl 1:23-40